Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.4 - $0.9 $111,894 - $251,761
-279,735 Reduced 74.97%
93,376 $45,000
Q1 2022

May 16, 2022

SELL
$0.72 - $1.54 $240,361 - $514,105
-333,835 Reduced 47.22%
373,111 $337,000
Q4 2021

Feb 14, 2022

BUY
$1.22 - $2.5 $862,474 - $1.77 Million
706,946 New
706,946 $862,000
Q1 2021

May 17, 2021

SELL
$3.93 - $6.68 $559,632 - $951,232
-142,400 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$5.02 - $6.59 $201,517 - $264,542
-40,143 Reduced 21.99%
142,400 $748,000
Q3 2020

Nov 16, 2020

SELL
$5.41 - $8.67 $270,521 - $433,534
-50,004 Reduced 21.5%
182,543 $1.03 Million
Q2 2020

Aug 14, 2020

BUY
$8.05 - $29.44 $1.87 Million - $6.85 Million
232,547 New
232,547 $1.87 Million

About NeuroBo Pharmaceuticals, Inc.


  • Ticker NRBO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 888,693
  • Market Cap $2.4M
  • Description
  • NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the tr...
More about NRBO
Track This Portfolio

Track Sabby Management, LLC Portfolio

Follow Sabby Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sabby Management, LLC with notifications on news.